Below are all the abstracts related to ROS1 NSCLC listed in the scientific program for the 2019 IASLC World Conference on Lung Cancer in Barcelona, Spain September 7-10. While the times and locations of sessions may change, the numbers and names will not. ES14 – What First Line in Oncogene Addicted NSCLC 15:15 – 16:45 … Continue reading ROS1 abstracts at #WCLC19
“The young boy was running out of time. His brain tumor was growing so fast that he had trouble putting words together. All standard cancer treatments had failed. Then last summer the child started taking an experimental pill that targeted a rare genetic mutation found inside his tumor. Within months, the malignant growth started to … Continue reading Entrectinib -Roche’s Gene-Targeting Drug Shows Promise in Child Brain Tumors
On May 16, 2019, ROS1der co-founder Janet Freeman-Daily interviewed ROS1 expert D Ross Camidge, MD, PhD, Director of Thoracic Oncology and the Joyce Zeff Chair in Lung Cancer Research at the University of Colorado in a Zoom Webinar. We discussed questions that have arisen among experienced patients in The ROS1ders regarding diagnosis, treatment, and research … Continue reading The ROS1ders Interview Dr. Ross Camidge (16-May-2019)
Yesterday the pan-Canadian Oncology Drug Review (pCODR) process gave a positive initial recommendation for first-line crizotinib for ROS1+ NSCLC based on clear phase 2 data & Real World Evidence. A randomized Phase 3 study was not required. This is an essential step towards getting crizotinib reimbursed for patients across Canada. This submission was led by … Continue reading pCODR recommends pan-Canadian crizotinib first-line for ROS1+ NSCLC
Yesterday the FDA has granted Priority Review for entrectinib for the treatment of ROS1-positive NSCLC and NTRK fusion-positive solid tumors. The FDA is expected to make a decision on approval by August 18, 2019. FDA Grants Priority Review to Genentech’s Personalized Medicine Entrectinib
I’m Janet Freeman-Daily, a cofounder of The ROS1ders. I’m writing this post in response to some of the comments we’ve seen recently in our private Facebook group “ROS1 Positive (ROS1+) Cancer.” Many of our members who have ROS1+ cancers take the targeted therapy crizotinib (Xalkori), a tyrosine kinase inhibitor (TKI). It was approved by the … Continue reading Thinking about a “drug vacation” from crizotinib? Read this first!